We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Zhong Yuan BioTechnology Holdings Ltd (QB) | USOTC:ZHYBF | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.99 | 2.33 | 5.75 | 0.00 | 21:00:04 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 under the
Securities Exchange Act of 1934
February 28, 2022
Commission File Number: 000-55631
ZHONG YUAN BIO-TECHNOLOGY HOLDINGS LIMITED
(Translation of registrant’s name into English)
Suite 901, Tesbury Centre
28 Queen’s Road East
Wanchai, Hong Kong
(Address of principal executive office)
CHANG Ting Ting
Telephone: + 852 2919-8916
Email: tinachang@zybioholdings.com
Suite 901, Tesbury Centre
28 Queen’s Road East
Wanchai, Hong Kong
(Name, Telephone, email and/or fax number and address of Company Contact Person)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____
|
CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS
This Form 6-K and other reports filed by the Company from time to time with the Securities and Exchange Commission (collectively the “Filings”) contain or may contain forward-looking statements and information that are based upon beliefs of, and information currently available to, the Company’s management as well as estimates and assumptions made by the Company’s management. When used in the filings the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan” or the negative of these terms and similar expressions as they relate to the Company or the Company’s management identify forward-looking statements. Such statements reflect the current view of the Company with respect to future events and are subject to risks, uncertainties, assumptions and other factors. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.
Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.
CHANGE OF CERTIFYING ACCOUNTANTS
Dismissal of Previous Independent Registered Public Accounting Firm
On February 25, 2022, the Company dismissed Centurion ZD CPA & Co (“Centurion ZD”) as its independent registered public accounting firm. The report of Centurion ZD on our financial statements for the fiscal year ended March 31, 2021 contained no adverse opinion or disclaimer of opinion and was not modified. The decision to change the independent accountant was approved and ratified by our Board of Directors (“Board of Directors”) on February 25, 2022.
During our most recent fiscal year ended March 31, 2021 and through the date of this report, we have had no disagreements with Centurion ZD on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Centurion ZD, would have caused it to make reference to the subject matter of such disagreements in its report on our financial statements for such period.
During our most recent fiscal year ended March 31, 2021 and through the date of this report, there have been no reportable events as defined under Item 304(a)(1)(v) of Regulation S-K adopted by the Securities and Exchange Commission (the “SEC”).
We provided Centurion ZD with a copy of this disclosure before the filing was made with the SEC. We requested that Centurion ZD provide us with a letter addressed to the SEC stating whether or not it agrees with the above statements, and we received a letter from Centurion ZD stating that it agrees with the above statements. A copy of such letter, dated as of February 28, 2022 is filed as Exhibit 99.1 to this report.
Appointment of New Independent Registered Public Accounting Firm
The Company has engaged K. R. Margetson Ltd. (“Margetson”) as our new independent registered public accounting firm.
During the two most recent fiscal years and through the date of our engagement, we did not consult with Margetson regarding either: (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on our financial statements; or (ii) any matter that was either the subject of a disagreement or a reportable event (as defined in Item 304(a)(1)(v) of Regulation S-K). In approving the selection of Margetson as the Company’s new independent registered public accounting firm, our Board of Directors considered all relevant factors, including the fact that Margetson is not located in China or Hong Kong.
EXHIBITS
Exhibit Description
99.1 | Letter from Centurion ZD CPA & Co to Securities and Exchange Commission dated February 28, 2022. |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 28, 2022 | ZHONG YUAN BIO-TECHNOLOGY HOLDINGS LIMITED |
/s/ CHANG, Ting Ting | |
Name: CHANG, Ting Ting Title: Chief Executive Officer |
/s/ PANG Fung Ming | |
Name: PANG Fung Ming Title: Chief Financial Officer and Director |
1 Year Zhong Yuan BioTechnology (QB) Chart |
1 Month Zhong Yuan BioTechnology (QB) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions